17:49 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts BAP1-knockout, transgenic mice with melanocyte-specific expression of mutant human GNA11 could be used to screen therapies for metastatic uveal melanoma. Mice with systemic BAP1 knockout and tamoxifen-induced expression of the human...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

Tazemetostat: Phase II started

Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in 67 patients. The first part will evaluate safety and pharmacokinetics of tazemetostat in 12 patients regardless of BRCA1-associated...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BRCA1-associated protein 1 (BAP1); enhancer of zeste homolog 2 (EZH2)

Cancer INDICATION: Mesothelioma; myeloproliferative disorder In vitro and mouse studies suggest inhibiting EZH2 could help treat BAP1-mutant cancers and myeloproliferative disorder. In human BAP1-mutant mesothelioma cell lines, EZH2 knockdown or a small molecule inhibitor of...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Castle Biosciences, Washington University deal

Castle received exclusive, worldwide rights from the university to IP related to the BRCA1-associated protein 1 (BAP1) gene. Castle will incorporate BAP1 in its DecisionDx-UM assay, which detects the likelihood of metastasis in uveal melanoma...
08:00 , Nov 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma BRCA1-associated protein 1 (BAP1) Studies in patient tissue samples and in cell culture suggest that mutant BAP1 contributes to metastatic melanoma and could be...
08:00 , Mar 2, 1998 |  BC Week In Review  |  Company News

The Wistar Institute other research news

The Institute reported in Oncogene that it has identified BRCA1-associated protein-1 (BAP1), an enzyme that binds to the normal form of the BRCA1 protein not associated with breast cancer. BAP1, which is expressed during breast...